HCW Biologics (HCWB) Operating Expenses (2020 - 2026)

HCW Biologics (HCWB) has reported Operating Expenses for 7 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 11.34% year-over-year to $3.1 million; the trailing twelve-month figure through Jun 2026 stood at $14.3 million (up 15.06% YoY), and the FY2025 full-year result was $13.2 million, down 56.69% from the prior year.
• Operating Expenses eased to $3.1 million in Q2 2026 per HCWB's latest filing, from $4.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $15.3 million in Q2 2024 and bottomed at $2.0 million in Q1 2025.
• Historically, Operating Expenses has averaged $5.3 million across 5 years, with a median of $4.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 230.74% in 2024, then sank 77.37% in 2025.
• Over 5 years, Operating Expenses stood at $5.9 million in 2022, then surged by 85.68% to $11.0 million in 2023, then tumbled by 70.72% to $3.2 million in 2024, then soared by 38.46% to $4.5 million in 2025, then sank by 31.22% to $3.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $3.1 million, $4.5 million, and $3.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.